Rovelizumab, also known as LeukArrest and Hu23F2G, is a humanized monoclonal antibody which was an experimental immunosuppressive drug. It was developed...
5 KB (476 words) - 23:52, 17 July 2024
PRO 140† Quilizumab Ravulizumab Reslizumab Retifanlimab Rontalizumab Rovelizumab Ruplizumab Samalizumab Satralizumab Siplizumab Spartalizumab† Talizumab...
38 KB (4,316 words) - 10:24, 26 August 2024
Inebilizumab Maslimomab Morolimumab Ofatumumab Pexelizumab Reslizumab Rovelizumab Siplizumab Talizumab Telimomab aritox Teprotumumab Vapaliximab Vepalimomab...
7 KB (299 words) - 13:45, 27 April 2024
cancer Rovalpituzumab tesirine mab humanized DLL3 small cell lung cancer Rovelizumab LeukArrest mab humanized CD11, CD18 Y haemorrhagic shock etc. Rozanolixizumab...
136 KB (4,020 words) - 06:13, 27 September 2024
(USAN) Rotigotine (USAN) rotoxamine (INN) rotraxate (INN) Rovamycine rovelizumab (INN) Rowasa roxadimate (INN) Roxanol roxarsone (INN) roxatidine (INN)...
13 KB (584 words) - 06:16, 21 September 2024
Inebilizumab Maslimomab Morolimumab Ofatumumab Pexelizumab Reslizumab Rovelizumab Siplizumab Talizumab Telimomab aritox Teprotumumab Vapaliximab Vepalimomab...
38 KB (2,656 words) - 12:11, 30 October 2023
PRO 140† Quilizumab Ravulizumab Reslizumab Retifanlimab Rontalizumab Rovelizumab Ruplizumab Samalizumab Satralizumab Siplizumab Spartalizumab† Talizumab...
2 KB (87 words) - 01:28, 30 May 2023
emphysema, chronic bronchitis, and acute respiratory distress syndrome. Rovelizumab, trade-named LeukArrest and also known as Hu23F2G, was developed to treat...
44 KB (4,443 words) - 22:02, 31 August 2024
drugs, but none of them have been successful. Among them are Icos's rovelizumab (LeukArrest), and two drugs developed by Protein Design Labs and Centocor...
5 KB (424 words) - 09:41, 18 August 2023